Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 27, Issue 20, Pages 2381-2386Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612826666201029164036
Keywords
LncRNA FTX; cancer; temporal lobe epilepsy; cirrhosis; heart failure; osteosarcoma
Categories
Funding
- National Natural Science Foundation of China [81773959, 81974528]
- Open Foundation for Tumor Microenvironment and Immunotherapy Key Laboratory of Hubei province in China [2019KZL09]
- Health commission of Hubei Province Scientific Research Project in China [WJ2019H527]
Ask authors/readers for more resources
LncRNA FTX is abnormally increased in various tumors, while its expression level decreases in certain diseases. FTX may be an important regulatory factor and a potential therapeutic target in cancers.
Background: LncRNA is a kind of non-coding RNA and its research is more popular in recent years, which has more than 200 nucleotides. It plays a significant part in various biological functions, including chromosome modification, genome modification, transcriptional activation, transcriptional interference, and other processes. FTX, at the center of the X chromosome inactivation and it has been shown that lncRNA FTX regulates cancer cells' development, migration, and invasion in many studies. Methods: Relevant literature was collected through the PubMed system search and is summarized in this article. Results: LncRNA FTX abnormally increased in tumor cells, such as liver cancer, stomach cancer, leukemia, renal cell carcinoma, colorectal cancer, glioma, osteosarcoma, etc. However, the expression level decreased in temporal lobe epilepsy, liver cirrhosis, heart failure, etc. Conclusion: FTX may be an important regulatory factor and a potential therapeutic target in cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available